表紙
市場調查報告書
商品編碼
1064970

三陰性乳癌治療的全球市場(2021年∼2027年): COVID-19影響分析,各治療類型,各給藥途徑,各流通管道,各終端用戶,各地區的規模,佔有率,預測

Triple-negative Breast Cancer Treatment Market with COVID-19 Impact Analysis, By Treatment Type, By Route Of Administration, By Distribution Channel, By End-User and By Region - Size, Share & Forecast from 2021-2027

出版日期: | 出版商: AnalystView Market Insights | 英文 302 Pages | 商品交期: 2-3個工作天內

價格
  • 全貌
  • 簡介
  • 目錄
簡介

全球三陰性乳癌治療的市場規模,2020年有6億2,000萬美元以上的市場規模,2021年∼2027年之間預計以4.5%以上的年複合成長率成長。

本報告提供全球三陰性乳癌治療市場相關調查分析,市場概要,市場的推動因素與阻礙因素的分析,COVID-19影響,各市場區隔、各地區的市場分析,競爭情形,企業簡介等資訊。

目錄

第1章 三陰性乳癌治療:市場概要

第2章 摘要整理

  • 市場明細
    • 各治療類型
    • 各給藥途徑
    • 各流通管道
    • 各終端用戶
    • 各地區
  • 競爭洞察

第3章 三陰性乳癌治療:主要的市場趨勢

  • 推動市場要素
    • 推動市場要素的影響分析
  • 市場阻礙因素
    • 市場阻礙因素的影響分析
  • 市場機會
  • 市場未來趨勢

第4章 三陰性乳癌治療:產業調查

  • 波特的五力分析
  • 行銷策略分析
  • 成長預測製圖
  • 法律規範分析

第5章 三陰性乳癌治療市場:COVID-19影響分析

  • COVID-19前
  • COVID-19後
    • 最高成果市場區隔
    • 邊際成長市場區隔
    • 最大損失市場區隔
    • 邊際損失市場區隔

第6章 三陰性乳癌治療市場:市場形勢

  • 市場佔有率分析(2020年)
  • 主要創新者分析
  • 各主要製造商的明細資料
    • 現有企業的分析
    • 新興企業的分析

第7章 三陰性乳癌治療市場:各治療類型

  • 概要

第8章 三陰性乳癌治療市場:各給藥途徑

  • 概要

第9章 三陰性乳癌治療市場:各流通管道

  • 概要

第10章 三陰性乳癌治療市場:各終端用戶

  • 概要

第11章 三陰性乳癌治療市場:各地區

  • 簡介
  • 北美
  • 歐洲
  • 亞太地區
  • 南美
  • 中東、非洲

第12章 供應商的分析

  • 競爭儀表板
  • 企業簡介
    • AstraZeneca PLC
    • Pfizer Inc.
    • F. Hoffman-La Roche Ltd.
    • Bristol-Myers Squibb Company
    • Novartis AG
    • Mylan NV
    • Eli Lilly Company
    • Celgene Corporation
    • Sanofi SA
    • Johnson &Johnson Drug Type Inc.

第13章 分析師的總括的展望

第14章 附錄

目錄
Product Code: ANV774

REPORT HIGHLIGHT

The market for Triple-negative breast cancer treatment market is expected to be worth more than $620 million in 2020, expanding at a CAGR of more than 4.5% from 2021 to 2027.

Triple-negative breast cancer is characterized by the absence of progesterone and estrogen receptors. Triple-negative breast cancer does not respond to hormonal therapy and necessitates a combination of surgical procedures.

Market Dynamics

Increased demand for triple-negative breast cancer treatment solutions is being driven by the rising prevalence of breast cancer and blood-related illnesses among the growing population. Increased focus on research and development in therapeutic areas like oncology, as well as the acceptance of innovative treatment regimens for breast cancer, are projected to drive the triple-negative breast cancer treatment market size to new heights in the near future. According to the World Health Organization (WHO), cancer is the second-leading cause of death worldwide, accounting for approximately one in every six deaths, with an estimated 9.6 million deaths in 2018. According to the WHO, approximately 2.09 million cases of breast cancer were discovered worldwide. As a result, rising breast cancer prevalence, an aging population, and changing lifestyles are expected to drive the growth of the triple-negative breast cancer treatment market.

The market for Triple Negative Breast Cancer treatment is expanding due to an increase in the number of TNBC patients, advancements in medical technology, and the growing need for effective breast cancer treatment. However, the COVID-19 pandemic has a short-term negative impact on the TNBC market. The COVID-19 pandemic has caused a slew of market issues, including labor shortages and transportation restrictions.

Segmentation Analysis:

Triple-Negative Breast Cancer treatment is segmented as treatment type, route of administration, end-users, and distribution channel.

The triple-Negative Breast Cancer treatment market is classified into immunotherapy, targeted therapy, chemotherapy, and others based on treatment type.

The route of administration segment for the triple-negative breast cancer market is divided into oral, parenteral, and others.

In terms of end-users, the triple-negative breast cancer market is segmented into hospitals, home care, specialty clinics, and others.

The triple-negative breast cancer market has been segmented by distribution channel into hospital pharmacy, internet pharmacy, and retail pharmacy.

Competitive Landscape:

Collaborations between major players in the creation and research of innovative and novel drugs are boosting the market's growth. In addition, the market is being fuelled by a strong pipeline of medications in clinical development for the diagnosis and treatment of triple-negative breast cancer. The evolution of nanotechnology has been identified as a major trend in the treatment of triple-negative breast cancer. Nanotechnology has proven to be a useful technique in the treatment of triple-negative breast cancer.

Major players are investing to develop innovative treatment techniques. For instance, CEL-SCI produced immunotherapy to treat COVID-19 in March 2020, which would lessen tissue damage and other disorders. Several other viral diseases, some types of cancer, allergic asthma and allergy, select CNS diseases such as Alzheimer's, and autoimmune diseases such as rheumatoid arthritis have all been linked to antigenic peptide(s) sequences.

Key features of the study:

  • This proposed research study on Triple Negative Breast Cancer treatment market provides market size (US$ million), compound annual growth rate (CAGR %) and forecast estimation (2021-2027), considering 2020 as the base year
  • The research report elucidates potential growth opportunities across different segments/countries and explains attractive investment proposition matrix for Triple Negative Breast Cancer treatment market
  • The overall report identifies new investment opportunities, challenges faced by established players, and growth factors to sustain in the Triple Negative Breast Cancer treatment market
  • Impact of COVID-19 on Triple Negative Breast Cancer treatment market size, forecast, CAGR, and market dynamics are discussed in detail under the research scope. Detailed insight on Triple Negative Breast Cancer treatment market post-COVID will also be covered.
  • In order to give the users of this report a comprehensive view on the Triple Negative Breast Cancer treatment market, we have also included competitive landscape and key innovator analysis for the Triple Negative Breast Cancer treatment market
  • The study encompasses a growth prospect mapping analysis, wherein all the industry segments are benchmarked based on their market size, growth rate and attractiveness.
  • The report offers detailed company profiling featuring major market participants which will help users to understand their financial information and strategic initiatives of players operating in the Triple Negative Breast Cancer treatment market.
  • In addition, the report also unveil the important acquisitions & mergers, collaborations & joint ventures, new launch, research & development, regional expansion of major participants involved in the market on global as well as regional level.
  • The global Triple Negative Breast Cancer treatment market report primarily caters to various stakeholders in this industry including suppliers, investors, new entrants, distributors, and financial analysts

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL TRIPLE-NEGATIVE BREAST CANCER TREATMENT MARKET KEY PLAYERS

  • AstraZeneca PLC
  • Pfizer Inc.
  • F. Hoffman - La Roche Ltd.
  • Bristol-Myers Squibb Company
  • Novartis AG
  • Mylan N.V.
  • Eli Lilly Company
  • Celgene Corporation
  • Sanofi S.A.
  • Johnson & Johnson Drug Type Inc.
  • Others

GLOBAL TRIPLE-NEGATIVE BREAST CANCER TREATMENT MARKET, BY TREATMENT TYPE

  • Chemotherapy
  • Targeted Therapy
  • Immunotherapy
  • Others

GLOBAL TRIPLE-NEGATIVE BREAST CANCER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION

  • Oral
  • Parenteral
  • Others

GLOBAL TRIPLE-NEGATIVE BREAST CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL

  • Hospital Pharmacy
  • Internet Pharmacy
  • Retail Pharmacy

GLOBAL TRIPLE-NEGATIVE BREAST CANCER TREATMENT MARKET, BY END-USERS

  • Hospitals
  • Homecare
  • Specialty Clinics
  • Others

GLOBAL TRIPLE-NEGATIVE BREAST CANCER TREATMENT MARKET, REGION

  • North America
    • The U.S.
    • Canada
  • Europe
    • Germany
    • France
    • Italy
    • Spain
    • United Kingdom
    • Rest of Europe
  • Asia Pacific
    • India
    • China
    • South Korea
    • Japan
    • Singapore
    • Rest of APAC
  • Latin America
    • Brazil
    • Mexico
    • Argentina
    • Rest of LATAM
  • The Middle East and Africa
    • Saudi Arabia
    • United Arab Emirates
    • Rest of MEA

TABLE OF CONTENT

1. Triple-negative breast cancer treatment Market Overview

  • 1.1. Study Scope

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Market Snippet by Treatment Type
    • 2.1.2. Market Snippet by Route of Administration
    • 2.1.3. Market Snippet by Distribution Channel
    • 2.1.4. Market Snippet by End-User
    • 2.1.5. Market Snippet by Region
  • 2.2. Competitive Insights

3. Triple-negative breast cancer treatment Key Market Trends

  • 3.1. Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Future Trends

4. Triple-negative breast cancer treatment Industry Study

  • 4.1. Porter's Five Forces Analysis
  • 4.2. Marketing Strategy Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Triple-negative breast cancer treatment Market: COVID-19 Impact Analysis

  • 5.1. Pre-COVID-19 Impact Analysis
  • 5.2. Post-COVID-19 Impact Analysis
    • 5.2.1. Top Performing Segments
    • 5.2.2. Marginal Growth Segments
    • 5.2.3. Top Looser Segments
    • 5.2.4. Marginal Loss Segments

6. Triple-negative breast cancer treatment Market Landscape

  • 6.1. Market Share Analysis, 2020
  • 6.2. Key Innovators Analysis
  • 6.3. Breakdown Data, by Key Manufacturer
    • 6.3.1. Established Players' Analysis
    • 6.3.2. Emerging Players' Analysis

7. Triple-negative breast cancer treatment Market - By Treatment Type

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Treatment Type, 2020 & 2027 (%)
    • 7.1.2. Chemotherapy
    • 7.1.3. Targeted Therapy
    • 7.1.4. Immunotherapy
    • 7.1.5. Others

8. Triple-negative breast cancer treatment Market - By Route of Administration

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Route of Administration, 2020 & 2027 (%)
    • 8.1.2. Oral
    • 8.1.3. Parenteral
    • 8.1.4. Others

9. Triple-negative breast cancer treatment Market - By Distribution Channel

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By Distribution Channel, 2020 & 2027 (%)
    • 9.1.2. Hospital Pharmacy
    • 9.1.3. Internet Pharmacy
    • 9.1.4. Retail Pharmacy

10. Triple-negative breast cancer treatment Market - By End-User

  • 10.1. Overview
    • 10.1.1. Hospitals
    • 10.1.2. Homecare
    • 10.1.3. Specialty Clinics
    • 10.1.4. Others

11. Triple-negative breast cancer treatment Market- By Geography

  • 11.1. Introduction
    • 11.1.1. Segment Share Analysis, By Geography, 2020 & 2027 (%)
  • 11.2. North America
    • 11.2.1. Overview
    • 11.2.2. Key Manufacturers in North America
    • 11.2.3. North America Market Size and Forecast, By Country, 2016 - 2027 (US$ Million)
    • 11.2.4. North America Market Size and Forecast, By Treatment Type, 2016 - 2027 (US$ Million)
    • 11.2.5. North America Market Size and Forecast, By Route of Administration, 2016 - 2027 (US$ Million)
    • 11.2.6. North America Market Size and Forecast, By Distribution Channel, 2016 - 2027 (US$ Million)
    • 11.2.7. North America Market Size and Forecast, By End-User, 2016 - 2027 (US$ Million)
    • 11.2.8. U.S.
      • 11.2.8.1. Overview
      • 11.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 - 2027, (US$ Million)
      • 11.2.8.3. U.S. Market Size and Forecast, By Treatment Type, 2016 - 2027 (US$ Million)
      • 11.2.8.4. U.S. Market Size and Forecast, By Route of Administration, 2016 - 2027 (US$ Million)
      • 11.2.8.5. U.S. Market Size and Forecast, By Distribution Channel, 2016 - 2027 (US$ Million)
      • 11.2.8.6. U.S. Market Size and Forecast, By End-User, 2016 - 2027 (US$ Million)
      • 11.2.8.7.
    • 11.2.9. Canada
      • 11.2.9.1. Overview
      • 11.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 - 2027, (US$ Million)
      • 1.1.1.1. Canada Market Size and Forecast, By Treatment Type, 2016 - 2027 (US$ Million)
      • 1.1.1.2. Canada Market Size and Forecast, By Route of Administration, 2016 - 2027 (US$ Million)
      • 1.1.1.3. Canada Market Size and Forecast, By Distribution Channel, 2016 - 2027 (US$ Million)
      • 1.1.1.4. Canada Market Size and Forecast, By End-User, 2016 - 2027 (US$ Million)
  • 11.3. Europe
    • 11.3.1. Overview
    • 11.3.2. Key Manufacturers in Europe
    • 11.3.3. Europe Market Size and Forecast, By Country, 2016 - 2027 (US$ Million)
    • 11.3.4. Europe Market Size and Forecast, By Treatment Type, 2016 - 2027 (US$ Million)
    • 11.3.5. Europe Market Size and Forecast, By Route of Administration, 2016 - 2027 (US$ Million)
    • 11.3.6. Europe Market Size and Forecast, By Distribution Channel, 2016 - 2027 (US$ Million)
    • 11.3.7. Europe Market Size and Forecast, By End-User, 2016 - 2027 (US$ Million)
    • 11.3.8. Germany
      • 11.3.8.1. Overview
      • 11.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 - 2027, (US$ Million)
      • 11.3.8.3. Germany Market Size and Forecast, By Treatment Type, 2016 - 2027 (US$ Million)
      • 11.3.8.4. Germany Market Size and Forecast, By Route of Administration, 2016 - 2027 (US$ Million)
      • 11.3.8.5. Germany Market Size and Forecast, By Distribution Channel, 2016 - 2027 (US$ Million)
      • 11.3.8.6. Germany Market Size and Forecast, By End-User, 2016 - 2027 (US$ Million)
    • 11.3.9. Italy
      • 11.3.9.1. Overview
      • 11.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 - 2027, (US$ Million)
      • 11.3.9.3. Italy Market Size and Forecast, By Treatment Type, 2016 - 2027 (US$ Million)
      • 11.3.9.4. Italy Market Size and Forecast, By Route of Administration, 2016 - 2027 (US$ Million)
      • 11.3.9.5. Italy Market Size and Forecast, By Distribution Channel, 2016 - 2027 (US$ Million)
      • 11.3.9.6. Italy Market Size and Forecast, By End-User, 2016 - 2027 (US$ Million)
    • 11.3.10. United Kingdom
      • 11.3.10.1. Overview
      • 11.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 - 2027, (US$ Million)
      • 11.3.10.3. United Kingdom Market Size and Forecast, By Treatment Type, 2016 - 2027 (US$ Million)
      • 11.3.10.4. United Kingdom Market Size and Forecast, By Route of Administration, 2016 - 2027 (US$ Million)
      • 11.3.10.5. United Kingdom Market Size and Forecast, By Distribution Channel, 2016 - 2027 (US$ Million)
      • 11.3.10.6. United Kingdom Market Size and Forecast, By End-User, 2016 - 2027 (US$ Million)
    • 11.3.11. France
      • 11.3.11.1. Overview
      • 11.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 - 2027, (US$ Million)
      • 11.3.11.3. France Market Size and Forecast, By Treatment Type, 2016 - 2027 (US$ Million)
      • 11.3.11.4. France Market Size and Forecast, By Route of Administration, 2016 - 2027 (US$ Million)
      • 11.3.11.5. France Market Size and Forecast, By Distribution Channel, 2016 - 2027 (US$ Million)
      • 11.3.11.6. France Market Size and Forecast, By End-User, 2016 - 2027 (US$ Million)
    • 11.3.12. Rest of Europe
      • 11.3.12.1. Overview
      • 11.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 - 2027, (US$ Million)
      • 11.3.12.3. Rest of the Europe Market Size and Forecast, By Treatment Type, 2016 - 2027 (US$ Million)
      • 11.3.12.4. Rest of the Europe Market Size and Forecast, By Route of Administration, 2016 - 2027 (US$ Million)
      • 11.3.12.5. Rest of the Europe Market Size and Forecast, By Distribution Channel, 2016 - 2027 (US$ Million)
      • 11.3.12.6. Rest of the Europe Market Size and Forecast, By End-User, 2016 - 2027 (US$ Million)
  • 11.4. Asia Pacific (APAC)
    • 11.4.1. Overview
    • 11.4.2. Key Manufacturers in Asia Pacific
    • 11.4.3. Asia Pacific Market Size and Forecast, By Country, 2016 - 2027 (US$ Million)
    • 11.4.4. Asia Pacific Market Size and Forecast, By Treatment Type, 2016 - 2027 (US$ Million)
    • 11.4.5. Asia Pacific Market Size and Forecast, By Route of Administration, 2016 - 2027 (US$ Million)
    • 11.4.6. Asia Pacific Market Size and Forecast, By Distribution Channel, 2016 - 2027 (US$ Million)
    • 11.4.7. Asia Pacific Market Size and Forecast, By End-User, 2016 - 2027 (US$ Million)
    • 11.4.8. India
      • 11.4.8.1. Overview
      • 11.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 - 2027, (US$ Million)
      • 11.4.8.3. India Market Size and Forecast, By Treatment Type, 2016 - 2027 (US$ Million)
      • 11.4.8.4. India Market Size and Forecast, By Route of Administration, 2016 - 2027 (US$ Million)
      • 11.4.8.5. India Market Size and Forecast, By Distribution Channel, 2016 - 2027 (US$ Million)
      • 11.4.8.6. India Market Size and Forecast, By End-User, 2016 - 2027 (US$ Million)
    • 11.4.9. China
      • 11.4.9.1. Overview
      • 11.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 - 2027, (US$ Million)
      • 11.4.9.3. China Market Size and Forecast, By Treatment Type, 2016 - 2027 (US$ Million)
      • 11.4.9.4. China Market Size and Forecast, By Route of Administration, 2016 - 2027 (US$ Million)
      • 11.4.9.5. China Market Size and Forecast, By Distribution Channel, 2016 - 2027 (US$ Million)
      • 11.4.9.6. China Market Size and Forecast, By End-User, 2016 - 2027 (US$ Million)
    • 11.4.10. Japan
      • 11.4.10.1. Overview
      • 11.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 - 2027, (US$ Million)
      • 11.4.10.3. Japan Market Size and Forecast, By Treatment Type, 2016 - 2027 (US$ Million)
      • 11.4.10.4. Japan Market Size and Forecast, By Route of Administration, 2016 - 2027 (US$ Million)
      • 11.4.10.5. Japan Market Size and Forecast, By Distribution Channel, 2016 - 2027 (US$ Million)
      • 11.4.10.6. Japan Market Size and Forecast, By End-User, 2016 - 2027 (US$ Million)
    • 11.4.11. South Korea
      • 11.4.11.1. Overview
      • 11.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 - 2027, (US$ Million)
      • 11.4.11.3. South Korea Market Size and Forecast, By Treatment Type, 2016 - 2027 (US$ Million)
      • 11.4.11.4. South Korea Market Size and Forecast, By Route of Administration, 2016 - 2027 (US$ Million)
      • 11.4.11.5. South Korea Market Size and Forecast, By Distribution Channel, 2016 - 2027 (US$ Million)
      • 11.4.11.6. South Korea Market Size and Forecast, By End-User, 2016 - 2027 (US$ Million)
    • 11.4.12. Rest of APAC
      • 11.4.12.1. Overview
      • 11.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 - 2027, (US$ Million)
      • 11.4.12.3. Rest of APAC Market Size and Forecast, By Treatment Type, 2016 - 2027 (US$ Million)
      • 11.4.12.4. Rest of APAC Market Size and Forecast, By Route of Administration, 2016 - 2027 (US$ Million)
      • 11.4.12.5. Rest of APAC Market Size and Forecast, By Distribution Channel, 2016 - 2027 (US$ Million)
      • 11.4.12.6. Rest of APAC Market Size and Forecast, By End-User, 2016 - 2027 (US$ Million)
  • 11.5. Latin America
    • 11.5.1. Overview
    • 11.5.2. Key Manufacturers in Latin America
    • 11.5.3. Latin America Market Size and Forecast, By Country, 2016 - 2027 (US$ Million)
    • 11.5.4. Latin America Market Size and Forecast, By Treatment Type, 2016 - 2027 (US$ Million)
    • 11.5.5. Latin America Market Size and Forecast, By Route of Administration, 2016 - 2027 (US$ Million)
    • 11.5.6. Latin America Market Size and Forecast, By Distribution Channel, 2016 - 2027 (US$ Million)
    • 11.5.7. Latin America Market Size and Forecast, By End-User, 2016 - 2027 (US$ Million)
    • 11.5.8. Brazil
      • 11.5.8.1. Overview
      • 11.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 - 2027, (US$ Million)
      • 11.5.8.3. Brazil Market Size and Forecast, By Treatment Type, 2016 - 2027 (US$ Million)
      • 11.5.8.4. Brazil Market Size and Forecast, By Route of Administration, 2016 - 2027 (US$ Million)
      • 11.5.8.5. Brazil Market Size and Forecast, By Distribution Channel, 2016 - 2027 (US$ Million)
      • 11.5.8.6. Brazil Market Size and Forecast, By End-User, 2016 - 2027 (US$ Million)
    • 11.5.9. Mexico
      • 11.5.9.1. Overview
      • 11.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 - 2027, (US$ Million)
      • 11.5.9.3. Mexico Market Size and Forecast, By Treatment Type, 2016 - 2027 (US$ Million)
      • 11.5.9.4. Mexico Market Size and Forecast, By Route of Administration, 2016 - 2027 (US$ Million)
      • 11.5.9.5. Mexico Market Size and Forecast, By Distribution Channel, 2016 - 2027 (US$ Million)
      • 11.5.9.6. Mexico Market Size and Forecast, By End-User, 2016 - 2027 (US$ Million)
    • 11.5.10. Argentina
      • 11.5.10.1. Overview
      • 11.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 - 2027, (US$ Million)
      • 11.5.10.3. Argentina Market Size and Forecast, By Treatment Type, 2016 - 2027 (US$ Million)
      • 11.5.10.4. Argentina Market Size and Forecast, By Route of Administration, 2016 - 2027 (US$ Million)
      • 11.5.10.5. Argentina Market Size and Forecast, By Distribution Channel, 2016 - 2027 (US$ Million)
      • 11.5.10.6. Argentina Market Size and Forecast, By End-User, 2016 - 2027 (US$ Million)
    • 11.5.11. Rest of LATAM
      • 11.5.11.1. Overview
      • 11.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 - 2027, (US$ Million)
      • 11.5.11.3. Rest of LATAM Market Size and Forecast, By Treatment Type, 2016 - 2027 (US$ Million)
      • 11.5.11.4. Rest of LATAM Market Size and Forecast, By Route of Administration, 2016 - 2027 (US$ Million)
      • 11.5.11.5. Rest of LATAM Market Size and Forecast, By End-User, 2016 - 2027 (US$ Million)
      • 11.5.11.6. Rest of LATAM Market Size and Forecast, By End-User, 2016 - 2027 (US$ Million)
  • 11.6. Middle East and Africa
    • 11.6.1. Overview
    • 11.6.2. Key Manufacturers in Middle East and Africa
    • 11.6.3. Middle East and Africa Market Size and Forecast, By Country, 2016 - 2027 (US$ Million)
    • 11.6.4. Middle East and Africa Market Size and Forecast, By Treatment Type, 2016 - 2027 (US$ Million)
    • 11.6.5. Middle East and Africa Market Size and Forecast, By Route of Administration, 2016 - 2027 (US$ Million)
    • 11.6.6. Middle East and Africa Market Size and Forecast, By Distribution Channel, 2016 - 2027 (US$ Million)
    • 11.6.7. Middle East and Africa Market Size and Forecast, By End-User, 2016 - 2027 (US$ Million)
    • 11.6.8. Saudi Arabia
      • 11.6.8.1. Overview
      • 11.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 - 2027, (US$ Million)
      • 11.6.8.3. Saudi Arabia Market Size and Forecast, By Treatment Type, 2016 - 2027 (US$ Million)
      • 11.6.8.4. Saudi Arabia Market Size and Forecast, By Route of Administration, 2016 - 2027 (US$ Million)
      • 11.6.8.5. Saudi Arabia Market Size and Forecast, By Distribution Channel, 2016 - 2027 (US$ Million)
      • 11.6.8.6. Saudi Arabia Market Size and Forecast, By End-User, 2016 - 2027 (US$ Million)
    • 11.6.9. United Arab Emirates
      • 11.6.9.1. Overview
      • 11.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 - 2027, (US$ Million)
      • 11.6.9.3. United Arab Emirates Market Size and Forecast, By Treatment Type, 2016 - 2027 (US$ Million)
      • 11.6.9.4. United Arab Emirates Market Size and Forecast, By Route of Administration, 2016 - 2027 (US$ Million)
      • 11.6.9.5. United Arab Emirates Market Size and Forecast, By Distribution Channel, 2016 - 2027 (US$ Million)
      • 11.6.9.6. United Arab Emirates Market Size and Forecast, By End-User, 2016 - 2027 (US$ Million)

12. Key Vendor Analysis

  • 12.1. Competitive Dashboard
  • 12.2. Company Profiles
    • 12.2.1. AstraZeneca PLC
    • 12.2.2. Pfizer Inc.
    • 12.2.3. F. Hoffman - La Roche Ltd.
    • 12.2.4. Bristol-Myers Squibb Company
    • 12.2.5. Novartis AG
    • 12.2.6. Mylan N.V.
    • 12.2.7. Eli Lilly Company
    • 12.2.8. Celgene Corporation
    • 12.2.9. Sanofi S.A.
    • 12.2.10. Johnson & Johnson Drug Type Inc.

13. 360 Degree Analyst View

14. Appendix

  • 14.1. Research Methodology
  • 14.2. References
  • 14.3. Abbreviations
  • 14.4. Disclaimer
  • 14.5. Contact Us

List of Tables

  • TABLE List of data sources
  • TABLE Market drivers; Impact Analysis
  • TABLE Market restraints; Impact Analysis
  • TABLE Triple-negative breast cancer treatment market: Treatment Types Snapshot (2020)
  • TABLE Segment Dashboard; Definition and Scope, by Treatment Types
  • TABLE Global Triple-negative breast cancer treatment market, by Treatment Types2016-2027 (USD Million)
  • TABLE Global Triple-negative breast cancer treatment market, by Route of Administration2016-2027 (USD Million)
  • TABLE Triple-negative breast cancer treatment market: Route of Administration Snapshot (2020)
  • TABLE Segment Dashboard; Definition and Scope, by Route of Administration
  • TABLE Global Triple-negative breast cancer treatment market, by Distribution Channel 2016-2027 (USD Million)
  • TABLE Triple-negative breast cancer treatment market: Distribution Channel Snapshot (2020)
  • TABLE Segment Dashboard; Definition and Scope, by Distribution Channel
  • TABLE Segment Dashboard; Definition and Scope, by End-User
  • TABLE Global Triple-negative breast cancer treatment market, by End-User 2016-2027 (USD Million)
  • TABLE Triple-negative breast cancer treatment market: End-User Snapshot (2020)
  • TABLE Triple-negative breast cancer treatment market: Regional snapshot (2020)
  • TABLE Segment Dashboard; Definition and Scope, by Region
  • TABLE Global Triple-negative breast cancer treatment market by Region 2016-2027 (USD Million)
  • TABLE North America Triple-negative breast cancer treatment market, by Country, 2016-2027 (USD Million)
  • TABLE North America Triple-negative breast cancer treatment market, by Treatment Types, 2016-2027 (USD Million)
  • TABLE North America Triple-negative breast cancer treatment market, by Route of Administration, 2016-2027 (USD Million)
  • TABLE North America Triple-negative breast cancer treatment market, by Distribution Channel, 2016-2027 (USD Million)
  • TABLE North America Triple-negative breast cancer treatment market, by End-User, 2016-2027 (USD Million)
  • TABLE Europe Triple-negative breast cancer treatment market, by Country, 2016-2027 (USD Million)
  • TABLE Europe Triple-negative breast cancer treatment market, by Treatment Types, 2016-2027 (USD Million)
  • TABLE Europe Triple-negative breast cancer treatment market, by Route of Administration, 2016-2027 (USD Million)
  • TABLE Europe Triple-negative breast cancer treatment market, by Distribution Channel, 2016-2027 (USD Million)
  • TABLE Europe Triple-negative breast cancer treatment market, by End-User, 2016-2027 (USD Million)
  • TABLE Asia Pacific Triple-negative breast cancer treatment market, by Country, 2016-2027 (USD Million)
  • TABLE Asia Pacific Triple-negative breast cancer treatment market, by Treatment Types, 2016-2027 (USD Million)
  • TABLE Asia Pacific Triple-negative breast cancer treatment market, by Route of Administration, 2016-2027 (USD Million)
  • TABLE Asia Pacific Triple-negative breast cancer treatment market, by Distribution Channel, 2016-2027 (USD Million)
  • TABLE Asia Pacific Triple-negative breast cancer treatment market, by End-User, 2016-2027 (USD Million)
  • TABLE Latin America Triple-negative breast cancer treatment market, by Country, 2016-2027 (USD Million)
  • TABLE Latin America Triple-negative breast cancer treatment market, by Treatment Type, 2016-2027 (USD Million)
  • TABLE Latin America Triple-negative breast cancer treatment market, by Route of Administration, 2016-2027 (USD Million)
  • TABLE Latin America Triple-negative breast cancer treatment market, by Distribution Channel, 2016-2027 (USD Million)
  • TABLE Latin America Triple-negative breast cancer treatment market, by End-Userel, 2016-2027 (USD Million)
  • TABLE Middle East and Africa Triple-negative breast cancer treatment market, by Country, 2016-2027 (USD Million)
  • TABLE Middle East and Africa Triple-negative breast cancer treatment market, by Treatment Type, 2016-2027 (USD Million)
  • TABLE Middle East and Africa Triple-negative breast cancer treatment market, by Route of Administration, 2016-2027 (USD Million)
  • TABLE Middle East and Africa Triple-negative breast cancer treatment market, by Distribution Channel, 2016-2027 (USD Million)
  • TABLE Middle East and Africa Triple-negative breast cancer treatment market, by End-User, 2016-2027 (USD Million)

List of Figures

  • FIGURE Triple-negative breast cancer treatment market segmentation
  • FIGURE Market research methodology
  • FIGURE Value chain analysis
  • FIGURE Porter's Five Forces Analysis
  • FIGURE Market Attractiveness Analysis
  • FIGURE COVID-19 Impact Analysis
  • FIGURE Pre & Post COVID-19 Impact Comparision Study
  • FIGURE Competitive Landscape; Key company market share analysis, 2020
  • FIGURE Treatment Type segment market share analysis, 2020 & 2027
  • FIGURE Treatment Type segment market size forecast and trend analysis, 2016 to 2027 (USD Million)
  • FIGURE Route of Administration segment market share analysis, 2020 & 2027
  • FIGURE Route of Administration segment market size forecast and trend analysis, 2016 to 2027 (USD Million)
  • FIGURE Distribution Channel segment market share analysis, 2020 & 2027
  • FIGURE Distribution Channel segment market size forecast and trend analysis, 2016 to 2027 (USD Million)
  • FIGURE Regional segment market share analysis, 2020 & 2027
  • FIGURE Regional segment market size forecast and trend analysis, 2016 to 2027 (USD Million)
  • FIGURE North America Triple-negative breast cancer treatment market share and leading players, 2020
  • FIGURE Europe Triple-negative breast cancer treatment market share and leading players, 2020
  • FIGURE Asia Pacific Triple-negative breast cancer treatment market share and leading players, 2020
  • FIGURE Latin America Triple-negative breast cancer treatment market share and leading players, 2020
  • FIGURE Middle East and Africa Triple-negative breast cancer treatment market share and leading players, 2020
  • FIGURE North America market share analysis by country, 2020
  • FIGURE U.S. Triple-negative breast cancer treatment market size, forecast and trend analysis, 2016 to 2027 (USD Million)
  • FIGURE Canada Triple-negative breast cancer treatment market size, forecast and trend analysis, 2016 to 2027 (USD Million)
  • FIGURE Europe Triple-negative breast cancer treatment market share analysis by country, 2020
  • FIGURE Germany Triple-negative breast cancer treatment market size, forecast and trend analysis, 2016 to 2027 (USD Million)
  • FIGURE Spain Triple-negative breast cancer treatment market size, forecast and trend analysis, 2016 to 2027 (USD Million)
  • FIGURE Italy Triple-negative breast cancer treatment market size, forecast and trend analysis, 2016 to 2027 (USD Million)
  • FIGURE UK Triple-negative breast cancer treatment market size, forecast and trend analysis, 2016 to 2027 (USD Million)
  • FIGURE France Triple-negative breast cancer treatment market size, forecast and trend analysis, 2016 to 2027 (USD Million)
  • FIGURE Rest of the Europe Triple-negative breast cancer treatment market size, forecast and trend analysis, 2016 to 2027 (USD Million)
  • FIGURE Asia Pacific Triple-negative breast cancer treatment market share analysis by country, 2020
  • FIGURE India Triple-negative breast cancer treatment market size, forecast and trend analysis, 2016 to 2027 (USD Million)
  • FIGURE China Triple-negative breast cancer treatment market size, forecast and trend analysis, 2016 to 2027 (USD Million)
  • FIGURE Japan Triple-negative breast cancer treatment market size, forecast and trend analysis, 2016 to 2027 (USD Million)
  • FIGURE South Korea Triple-negative breast cancer treatment market size, forecast and trend analysis, 2016 to 2027 (USD Million)
  • FIGURE Singapore Triple-negative breast cancer treatment market size, forecast and trend analysis, 2016 to 2027 (USD Million)
  • FIGURE Rest of APAC Triple-negative breast cancer treatment market size, forecast and trend analysis, 2016 to 2027 (USD Million)
  • FIGURE Latin America Triple-negative breast cancer treatment market size, forecast and trend analysis, 2016 to 2027 (USD Million)
  • FIGURE Latin America Triple-negative breast cancer treatment market share analysis by country, 2020
  • FIGURE Brazil Triple-negative breast cancer treatment market size, forecast and trend analysis, 2016 to 2027 (USD Million)
  • FIGURE Mexico Triple-negative breast cancer treatment market size, forecast and trend analysis, 2016 to 2027 (USD Million)
  • FIGURE Argentina Triple-negative breast cancer treatment market size, forecast and trend analysis, 2016 to 2027 (USD Million)
  • FIGURE Rest of LATAM Triple-negative breast cancer treatment market size, forecast and trend analysis, 2016 to 2027 (USD Million)
  • FIGURE Middle East and Africa Triple-negative breast cancer treatment market size, forecast and trend analysis, 2016 to 2027 (USD Million)
  • FIGURE Middle East and Africa Triple-negative breast cancer treatment market share analysis by country, 2020
  • FIGURE Saudi Arabia Triple-negative breast cancer treatment market size, forecast and trend analysis, 2016 to 2027 (USD Million)
  • FIGURE United Arab Emirates Triple-negative breast cancer treatment market size, forecast and trend analysis, 2016 to 2027 (USD Million)